TOKYO -- Japanese pharmaceutical Eisai is set to begin clinical trials in the U.S. for Eritoran, a drug initially developed as a treatment for severe sepsis but which could be useful in the fight against the new coronavirus, the company announced Wednesday.
Eritoran is being studied as a way of treating the virus while preventing lung injury.
